Clinical Cardiology Alert – April 1, 2004
April 1, 2004
View Issues
-
Late-Breaking Trials from the ACC Scientific Sessions in New Orleans
SYNERGY: The superior yield of the new Strategy of Enoxaparin, Revascularization, and Glycoprotein IIb/IIIa Inhibitors trial was presented by Dr. Kenneth Mahaffey and colleagues; WATCH: The Warfarin and Antiplatelet Trial in Chronic Heart failure was presented by Barry Massie, MD, from San Francisco. -
Mortality in Acute Coronary Syndromes
The use of combination evidence-based pharmacologic therapy was associated with lower 6-month mortality in patients with ACS. -
Women Really are Different! Gender Differences in Manifestations of CAD
Metabolic syndrome, but not obesity alone, was associated with a higher risk of cardiovascular events. The presence of MS in individuals with angiographic CAD at study entry substantially increased the likelihood of death and major adverse cardiovascular events. -
The Natural History of Lone Atrial Flutter
Patients with lone atrial flutter have an increased risk for thromboembolic events and use of anticoagulation is urged for all patients with atrial flutter who are older than 65. -
ICD Therapy In Congenital Heart Disease
ICD therapy is an effective management strategy in selected pediatric and congenital heart disease patients. -
Pharmacology Watch: Estrogen Found to Not Affect Heart Disease, Breast Cancer
The NIH has halted the estrogen-alone wing of the Womens Health Initiative a year before its scheduled end. -
Clinical Briefs in Primary Care Supplement